glp 1 gip triple agonist New strategies for the treatment of obesity and metabolic dysfunctions retatrutide triple agonist glp-1 gip
Description
A triple-hormone-receptor agonist, retatrutide , awaits FDA approval
Results In all, 39 pwIIH (mean age 33.6 years [SD 8.0], 92.3% female, median BMI 36.3 kg/m 2 [IQR 31.438.3]) were included, with 13 pwIIH being treated with GLP-1-RAs and remaining adherent to the treatment throughout the study
The EMA and FDA imposed a respective label (52, 53)
touchREV Endocrinol
MatthaeiSCatrinoiuDCelinskiAEkholmECookWHirshbergBet al
